http://www.summitplc.com/
Summit is an Oxford, UK based drug discovery company developing novel drug candidates to treat areas of high unmet medical need. Our strategy has evolved to focus on the development of two high-value clinical-stage programmes that target the fatal genetic disease Duchenne Muscular Dystrophy (DMD) and infections caused by the superbug C. difficile

Summit Corporation PLC : New Data Reported from...
HUG
Summit Corporation plc
('Summit' or 'the Company')

NEW DATA REPORTED FROM PRECLINICAL EFFICACY STUDY OF OGA INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND RELATED TAUOPATHIES

Improvement in symptoms of motor impairment, increased survival recorded

New data presented at International conference on dementia

Oxford, UK, 11 March 2013 - Summit (AIM: SUMM), a drug discovery and development company, reports new data from its OGA (O-linked N-acetylglucosaminidase) inhibitor programme for the treatment of tauopathies, a group of neurodegenerative diseases that includes Alzheimer's disease. The OGA inhibitors were evaluated in an in vivo disease model, with results showing trends to a positive impact on motor impairment symptoms and improved survival rates following daily oral dosing. These new data were presented at AD/PD(TM) 2013, the international conference on Alzheimer's and Parkinson's diseases held in Florence, Italy, 6-10 March.

"Following the strategic refocusing of Summit to commit all resources into advancing our two clinical-stage programmes, the completion of this study represents the natural conclusion of our involvement in this programme," commented Glyn Edwards, Chief Executive Officer of Summit. "The inhibition of the enzyme OGA has emerged as a potential new treatment paradigm for Alzheimer's disease and related tauopathies. These encouraging results further highlight the promise of the approach and of our OGA inhibitors, and will add greater depth to the scientific data package as we talk with perspective collaborators about taking this programme further into development."

Summary of Results from Preclinical Efficacy Study
The study evaluated the OGA inhibitors, previously identified using Seglin(TM) technology, in a transgenic tauopathy disease model to determine the effect that prolonged dosing had on motor impairments related to the disease and survival rates. The tauopathies are also characterised by reduced levels of O-GlcNAcylated tau protein and raised levels of hyper-phosphorylated tau protein. In summary, the results of daily oral dosing with the Seglin inhibitors for 10 weeks were:

A clear trend for reduced clasping, a clinical sign indicative of motor impairment, and improved survival rates compared to the untreated cohort;

A statistically significant increase in O-GlcNAcylated protein levels in the brain with the increased global levels maintained on repeat dosing to demonstrate that the OGA inhibitor accessed the brain compartment at therapeutically relevant concentrations;

No observed change in tau protein phosphorylation levels although this is consistent with precedent from the scientific literature;

No associated toxicity or adverse effects from prolonged dosing observed.

The full results were reported at AD/PD(TM) 2013 held in Florence, Italy, 6-10 March 2013, and a copy of the presentation is available from www.summitplc.com.

Summit reveals encouraging early data for potential Alzheimer’s treatment
7:29 am by Ian LyallThe new data were presented at an Alzheimer's and Parkinson's diseases conference in Florence that ended yesterday.

Drug developer Summit (LON:SUMM) has unveiled encouraging new data on its OGA inhibitor emanating from a pre-clinical study of efficacy in Alzheimer’s and related diseases.

The inhibition of OGA, or O-linked N-acetylglucosaminidase, has emerged as a potential method of treating tauopathies, a group of neurodegenerative diseases that includes Alzheimer's.

The in-vivo (in animal) disease model pointed to a positive impact on motor impairment symptoms and improved survival rates following daily oral dosing.

These new data were presented at an Alzheimer's and Parkinson's diseases conference in Florence that ended yesterday.

The company’s focus on its two lead drug candidates – one for Duchenne Muscular Dystrophy, the other for c.difficile infection – means the group will look for a partner to take research further.

"Following the strategic refocusing of Summit to commit all resources into advancing our two clinical-stage programmes, the completion of this study represents the natural conclusion of our involvement in this programme," said Summit chief executive Glyn Edwards.

"The inhibition of the enzyme OGA has emerged as a potential new treatment paradigm for Alzheimer's disease and related tauopathies. “These encouraging results further highlight the promise of the approach and of our OGA inhibitors, and will add greater depth to the scientific data package as we talk with prospective collaborators about taking this programme further into development

UPDATE: Summit reveals encouraging early data for potential Alzheimer’s treatment
2:29 pm by Ian LyallThe new data were presented at an Alzheimer's and Parkinson's diseases conference in Florence.

--adds broker update--




Drug developer Summit (LON:SUMM) has unveiled encouraging new data on its OGA inhibitor emanating from a pre-clinical study of efficacy in Alzheimer’s and related diseases.




The inhibition of OGA, or O-linked N-acetylglucosaminidase, has emerged as a potential method of treating tauopathies, a group of neurodegenerative diseases that includes Alzheimer's.




The in-vivo (in animal) disease model pointed to a positive impact on motor impairment symptoms and improved survival rates following daily oral dosing.




These new data were presented at an Alzheimer's and Parkinson's diseases conference in Florence in March.

The company’s focus on its two lead drug candidates – one for Duchenne Muscular Dystrophy, the other for c.difficile infection – means the group will look for a partner to take research further.




"Following the strategic refocusing of Summit to commit all resources into advancing our two clinical-stage programmes, the completion of this study represents the natural conclusion of our involvement in this programme," said Summit chief executive Glyn Edwards.




"The inhibition of the enzyme OGA has emerged as a potential new treatment paradigm for Alzheimer's disease and related tauopathies.




“These encouraging results further highlight the promise of the approach and of our OGA inhibitors, and will add greater depth to the scientific data package as we talk with prospective collaborators about taking this programme further into development."




Broker N+1 added that while the news highlights the potential the group has with its OGA inhibitors, it is not one of the main focuses of the group and adds little to the investment case.



N+1 is waiting for further news on the progress of its DMD and C.diff programmes, which could potentially generate “game changing” returns.




The broker has a 13.3p price target. Shares rose slightly to 4.26p

Broker round-up part 2 including Summit, Archipelago, Orogen Gold and Herencia
3:20 pm by John Harrington Philip Whiterow


Encouraging data from Summit’s (LON:SUMM) OGA inhibitor programme for the treatment of tauopathies, a group of diseases that includes Alzheimer’s disease, highlights the potential the group has with its OGA inhibitors, says N+1 Singer.

The broker is not making any change to its forecasts for Summit, however, because the study is not one of the main focuses of the group, and so therefore has little impact on the investment case.

“We await further news on the progress of its DMD and C.diff programmes, which could potentially generate game changing returns. We re-iterate a positive stance and 13.3p price target,” the broker said.

Looked at these for a long time but never ventured. Looks promising, mmmm!! Enjoy every ray of sunshine as it is minus one here and snow, freezing winds, so not nice. You are in the best place no thermals needed I would not think. Enjoy.

Its beautiful here. ;-)) Mid 70's. Looks like your weather is going backwards , saw the snow on the television. Thanks 3m.
Its been a real winter at home this year, can only get better I hope.

Closed up 16%

Be nice to double from here wouldn't it ?

Or even better that 90p back in 08.

Well, you never know....

Its all about keeping your nerve lol. The broker has a 13.3p target. This one does seem to move in the +8% to -8% range. Some more positive news and we will get there,

On Friday, Summit Corporation PLC (SUMM:LSE) closed at 5.25, 35.98% below its 52-week high of 8.20, set on Mar 15, 2012.


As of Mar 15, 2013, the consensus forecast amongst 3 polled investment analysts covering Summit Corporation plc advises that the company will outperform the market. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Feb 03, 2010. The previous consensus forecast advised investors to purchase equity in Summit Corporation plc.

hmm..might be a good time to buy more ...will think on it...there are afew others I'm thinking of going in on IAE is one of them..

Do you hold any other shares DC?

A lot at the moment, in most of of the stocks I have posted on. Some doing very well ie Wand, condor. A lot of them tend to drift back with lack of news one being edge resources, made a 100% + sold and back in again with the start of drilling. Been a great share that one. Had very good run the last few months. Just hope it lasts for all of us. Prefer being in the smaller company's
as the sp does move faster. There is more risk and if it goes right, more reward.

Summit outlines next steps in development of potentially breakthrough treatment
7:31 am by Ian LyallMaking the case: The company said it plans to present its utrophin modulator programme at what it described as a “major international conference” being held later this spring.

The drug discovery group Summit (LON:SUMM) has outlined its plans to further develop a potentially breakthrough treatment for muscle wasting disorder Duchenne Muscular Dystrophy.

Its lead drug candidate SMT C1100 is expected to enter clinical trials in patients in the second half of the year.

The study will be split into two. One part will concentrate on determining whether the drug is safe and well tolerated by children while assessing its C1100’s pharmacokinetics - in layman’s terms what the drug actually does to the body.

The treatment is designed stimulate production of a protein call utrophin, similar to dystrophin, which regulates muscle tone and function. It is hoped C1100 will restore and maintain healthy muscle function.

The second part of the study is a phase II trial that will include clinical markers of muscle health as well as levels of utrophin expression.

The biomarker programme has begun and includes the collaboration with Children’s National Medical Center of Washington DC, funded by the DMD organisation, The Foundation to Eradicate Duchenne.

The company said it plans to present its utrophin modulator programme at what it described as a “major international conference” being held later this spring.

Chief executive Glyn Edwards said: “Summit has a unique opportunity to develop a high-value franchise in utrophin modulation, an innovative therapeutic approach for DMD that targets all genetic forms of this devastating disease.

“These clinical trials will be the first to evaluate utrophin modulation in patients, and they aim to quickly establish clinical proof of concept for SMT C1100 through the use of novel biomarkers developed to measure aspects of muscle health.

“The biomarker work, to be conducted side by side with our clinical development programme, will strengthen our DMD franchise and will enhance the commercial value of this asset.”

First patient studies represent "significant acceleration" of plans, says Edwards
4:45 pm by Giles Gwinnett and Ian LyallThe treatment is designed to stimulate production of a protein called utrophin, similar to dystrophin, which regulates muscle tone and function. It is hoped C1100 will restore and maintain healthy muscle function

The first patient studies of Summit's (LON:SUMM) potentially breakthrough treatment for Duchenne Muscular Dystrophy (DMD) represents a "significant acceleration" in the development programme, says chief executive Glyn Edwards.

Lead drug candidate SMT C1100 is expected to enter clinical trials in patients in the second half of the year.

"I think there was a perception out in the market that we were not going to be getting into patients until next year but what we've announced here is that the first patient studies will be starting later this year, with more studies next year, obviously, but it's a significant acceleration of the programme from people's expectations," he explained to Proactive.

He said the firm had flagged up at the end of the last trial last year that it would take all of this year to get things ready for this next step but Edwards says hard work has brought this timeline forward.

As reported earlier, the study will be split into two.

One part will concentrate on determining whether the drug is safe and well tolerated by children while assessing its C1100’s pharmacokinetics - in layman’s terms what the drug actually does to the body.

The treatment is designed to stimulate production of a protein called utrophin, similar to dystrophin, which regulates muscle tone and function. It is hoped C1100 will restore and maintain healthy muscle function.

The second part of the study is a phase II trial that will include clinical markers of muscle health as well as levels of utrophin expression.

The biomarker programme has begun and includes the collaboration with Children’s National Medical Center of Washington DC, funded by the DMD organisation, The Foundation to Eradicate Duchenne.

The company also said earlier it plans to present its utrophin modulator programme at what it described as a “major international conference” being held later this spring.

Edwards told investors: “Summit has a unique opportunity to develop a high-value franchise in utrophin modulation, an innovative therapeutic approach for DMD that targets all genetic forms of this devastating disease.

“These clinical trials will be the first to evaluate utrophin modulation in patients, and they aim to quickly establish clinical proof of concept for SMT C1100 through the use of novel biomarkers developed to measure aspects of muscle health.

“The biomarker work, to be conducted side by side with our clinical development programme, will strengthen our DMD franchise and will enhance the commercial value of this asset.”

Shares dipped 0.92% to 5.375p.

hopefully we'll see more & stronger broker notes/recommendations soon

Summit schedules FY results

9 April 2013 | 14:59pm

StockMarketWire.com - Summit - a drug discovery and development company advancing therapies for Duchenne Muscular Dystrophy and C. difficile infections - will announce its preliminary results for the year to the end of January on 11 April.

At 2:59pm: [LON:SUMM] share price was +0.01p at 4.38p

Sold my holding

Summit antibiotic reveals encouraging early potential
By Ian Lyall April 24 2013, 7:32am The Summit drug candidate is part of a new class of antibiotics that are high potency and selective for one particular infection – in this case the so-called super-bug C.diff.The Summit drug candidate is part of a new class of antibiotics that are high potency and selective for one particular infection – in this case the so-called super-bug C.diff.

Summit (LON:SUMM) has unveiled encouraging early results from clinical trials on the antibiotic it is developing for C.difficile.

The phase I study on 56 healthy patients revealed SMT 19969 is both safe and well tolerated in the doses that would be required to treat patients.

The Summit drug candidate is part of a new class of antibiotics that are high potency and selective for one particular infection – in this case the so-called super-bug C.diff.

Researchers assessed 19969’s potential to target infections by looking at the gut flora in the volunteers. They found that it was “highly sparing” of gut flora with only the clostridia bacterial family reduced to levels below the limit of detection.

"The positive safety and tolerability of SMT 19969 in this human phase I trial is a major success," said Summit chief executive Glyn Edwards.

"The results of the gut flora analysis are particularly encouraging because they indicate that SMT 19969 could target C. difficile without undermining the natural balance of gut flora.

“This reinforces our belief that SMT 19969 can become a breakthrough treatment for this life-threatening disease."

Professor Mark Wilcox, Consultant Head of Microbiology at the Leeds Teaching Hospitals NHS Trust, added: “It is very encouraging that in human volunteers SMT 19969 is highly sparing of gut flora.

“This offers promise as a much needed alternative treatment for this potentially serious disease."